VEGFA and age-related macular degeneration: Intensive studies of this gene have led to the successful launch of an anti-VEGFR antibody and a VEGF-trap, the first two anti-angiogenesis therapeutic agents for metastatic cancers and age-related macular degeneration (AMD) [5].